Skip to main content
Canna~Fangled Abstracts

Pharmacophore-based virtual screening from phytocannabinoids as antagonist r-CB1

By August 17, 2022August 18th, 2022No Comments

. 2022 Aug 17;28(9):258.

doi: 10.1007/s00894-022-05219-3.

Lenir C Correia 1, Jaderson V Ferreira 1, Henrique B de Lima 1, Guilherme M Silva 2 3, Carlos H T P da Silva 2 3, Fábio A de Molfetta 4, Lorane I S Hage-Melim 5
Affiliations 

Abstract

Search for new pharmacological alternatives for obesity is based on the design and development of compounds that can aid in weight loss so that they can be used safely and effectively over a long period while maintaining their function. The endocannabinoid system is related to obesity by increasing orexigenic signals and reducing satiety signals. Cannabis sativa is a medicinal plant of polypharmaceutical potential that has been widely studied for various medicinal purposes. The in silico evaluation of their natural cannabinoids (also called phytocannabinoids) for anti-obesity purpose stems from the existence of synthetic cannabinoid compounds that have already presented this result, but which did not guarantee patient safety. In order to find new molecules from C. sativa phytocannabinoids, with the potential to interact peripherally with the pharmacological target cannabinoid receptor 1, a pharmacophore-based virtual screening was performed, including the evaluation of physicochemical, pharmacokinetic, toxicological predictions and molecular docking. The results obtained from the ZINC12 database pointed to Zinc 69 (ZINC33053402) and Zinc 70 (ZINC19084698) molecules as promising anti-obesity agents. Molecular dynamics (MD) studies disclose that both complexes were stable by analyzing the RMSD (root mean square deviation) values, and the binding free energy values demonstrate that the selected structures can interact and inhibit their catalytic activity.

Keywords: Molecular Dynamics, Molecular docking, Natural cannabinoids, Structure–activity relationship, Virtual Screening, rCB1 peripherals

References

    1. Ibsen MS, Connor M, Glass M, (2017) Cannabinoid CB1 and CB2 receptor signaling and bias. Cannabis and cannabinoid research 2:48–60. https://doi.org/10.1089/can.2016.0037
    1. World Health Organization, WHO (2014)
    1. Colon-Gonzalez F, Kim GW, Lin JE, Valentino MA, Waldman SA (2013) Obesity pharmacotherapy: what is next? Mol Aspects Med 34:71–83. https://doi.org/10.1016/j.mam.2012.10.005 – DOI – PubMed
    1. Romero-Zerbo SY, Bermúdez-Silva FJ (2014) Cannabinoids, eating behaviour, and energy homeostasis. Drug Test Anal 6:52–58. https://doi.org/10.1002/dta.1594 – DOI – PubMed
    1. Akbas F, Gasteyger C, Sjödin A, Astrup A, Larsen TM (2009) A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10:58–67. https://doi.org/10.1111/j.1467-789X.2008.00520.x – DOI – PubMed

Leave a Reply